Communiqués Modus Therapeutics Holding AB

Actions

MODTX

SE0015987904

Recherche biotechnologique et médicale

Temps Différé Nasdaq Stockholm 15:45:42 17/08/2026			Varia. 5j.	Varia. 1 janv.
0,4000 ^SEK	-5,21%		+5,82%	+31,58%

16/06	Modus Therapeutics Holding AB présente des données précliniques sur le sevuparin dans l'IRC avec anémie lors de l'EHA2026	CI
28/05	Modus Therapeutics Holding AB (Publ) approuve la nomination de nouveaux administrateurs	CI

Communiqués

18/06	Modus Therapeutics: SEVUSMART manuscript made available online ahead of peer review in Nature Communications	AQ
16/06	Modus Therapeutics reports on preclinical data on sevuparin in CKD with anemia presented at EHA2026	AQ
28/05	Annual General Meeting in Modus Therapeutics Holding AB (publ)	AQ
26/05	Modus Therapeutics publishes interim report for Q1 2026	AQ
21/05	Modus Therapeutics to present sevuparin data at the European Iron Club Meeting 2026 in Dublin	AQ
13/05	Modus Therapeutics to present preclinical data on sevuparin in CKD with anemia at EHA2026 in Stockholm	AQ
27/04	Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million	AQ
27/04	Notice to Annual General Meeting in Modus Therapeutics Holding	AQ
15/04	Modus Therapeutics Holding AB (publ) publishes annual report for the financial year 2025	AQ
14/04	KDventures AB subscribes for all of its warrants of series 2025/2026 in Modus Therapeutics	AQ
14/04	KDventures exercises its share of the portfolio company Modus Therapeutics’ warrant program TO2	AQ
13/04	Correction of Previously Communicated Press Release	AQ
13/04	Today the Exercise Period Begins for Modus Therapeutics Warrants Series 2025/2026	AQ
25/02	Modus Therapeutics publishes year-end report for 2025	AQ
10/12	First Patient Dosed in Part 2 of Modus Therapeutics’ Phase IIa Study in Chronic Kidney Disease with Anemia	AQ
10/12	Modus Therapeutics Holding: Discontinuing coverage	AQ
28/11	Modus Therapeutics Holding: Funding for next step secured – Q3 review	AQ
26/11	Modus Therapeutics publishes Interim report for the third quarter 2025	AQ
03/11	Modus Therapeutics receives regulatory approval for Part 2 of the Phase IIa study in CKD-with anemia	AQ
24/10/25	Change of Certified Adviser (CA) to Bergs Securities	AQ
18/09/25	Modus Therapeutics data to be presented at the 32nd Symposium on Glycosaminoglycans – sevuparin in focus for CKD with anemia	AQ
03/09/25	Modus resolves on compensation issue to guarantors in completed rights issue	AQ
27/08/25	Modus Therapeutics raises approximately SEK 28.3 million in oversubscribed unit issue	AQ
21/08/25	CEO Subscribes for Units in Modus’ Ongoing Rights Issue	AQ
11/08/25	Modus Therapeutics Holding AB Publishes Prospectus in Connection with the Upcoming Rights Issue of Units	AQ